22 August 2019GenericsRory O'Neill

Novo Nordisk seeks to block Mylan generic

Danish pharmaceutical company  Novo Nordisk has sued  Mylan in a US court over a proposed generic of diabetes drug  Victoza (liraglutide).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
24 March 2022   Novo Nordisk and Sandoz have settled an ongoing patent dispute over the blockbuster diabetes treatment Victoza before the companies were meant to face trial in April.

More on this story

Generics
24 March 2022   Novo Nordisk and Sandoz have settled an ongoing patent dispute over the blockbuster diabetes treatment Victoza before the companies were meant to face trial in April.

More on this story

Generics
24 March 2022   Novo Nordisk and Sandoz have settled an ongoing patent dispute over the blockbuster diabetes treatment Victoza before the companies were meant to face trial in April.